Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on Jun 05, 2025. Further, the company has submitted the Exchange a copy of Srutinizers report.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences held an Extra-Ordinary General Meeting (EGM) on June 5, 2025, via Video Conferencing, attended by 75 members and 6 directors. Three resolutions were passed with overwhelming shareholder approval: (1) An Ordinary Resolution to increase the Authorized Share Capital and amend the Memorandum of Association, approved with 99.9991% votes in favour. (2) A Special Resolution to issue up to 6,40,02,999 convertible warrants (each convertible into one equity share within 18 months) to the Promoter Group entity and certain identified non-promoter persons/entities, approved with 99.9509% votes in favour. (3) A Special Resolution to re-appoint Smt. Sudharani Jasti as Whole-time Director, approved with 99.9993% votes in favour. The Scrutinizer, D. Renuka (Practicing Company Secretary), confirmed all resolutions were passed with the requisite majority.
The approval of the preferential warrant issue of up to 6.4 crore convertible warrants signals a fundraising move that may lead to equity dilution for existing shareholders upon conversion. The increase in authorized share capital and re-appointment of the Whole-time Director suggest continuity in management and preparation for future capital expansion.